Tower Research Capital LLC TRC Has $86,000 Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)

Tower Research Capital LLC TRC trimmed its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) by 74.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 6,197 shares of the biotechnology company’s stock after selling 17,627 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Capricor Therapeutics were worth $86,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Summit Investment Advisors Inc. lifted its position in Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 1,345 shares during the period. Russell Investments Group Ltd. raised its position in shares of Capricor Therapeutics by 172.8% in the 4th quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 2,947 shares in the last quarter. AlphaQuest LLC bought a new stake in shares of Capricor Therapeutics during the 4th quarter worth approximately $78,000. New York State Common Retirement Fund boosted its position in shares of Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 5,000 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Capricor Therapeutics in the fourth quarter valued at approximately $91,000. 21.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on CAPR. HC Wainwright restated a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research note on Monday, March 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Capricor Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Trading Down 8.9 %

Capricor Therapeutics stock opened at $6.35 on Friday. The company has a market capitalization of $290.05 million, a PE ratio of -5.99 and a beta of 0.85. The stock has a 50-day moving average price of $11.16 and a two-hundred day moving average price of $14.23. Capricor Therapeutics Inc has a 12 month low of $3.52 and a 12 month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%. The business had revenue of $11.13 million during the quarter, compared to the consensus estimate of $9.87 million. As a group, analysts predict that Capricor Therapeutics Inc will post -1.21 earnings per share for the current fiscal year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.